Athira Pharma Presents Data from ACT-AD Phase 2 : vimarsana.

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...

Related Keywords

Australia , United States , Washington , Seattle , Mark Litton , Athira Pharma , Julie Rathbun , Hans Moebius , Instagram , Linkedin , Alzheimer Association International Conference , Twitter , National Institutes Of Health , Nasdaq , Exchange Commission , Athira Pharma Inc , Alzheimer Disease Cooperative Study , Securities Exchange , Chief Medical Officer , Mild To Moderate Alzheimer , First Results , Week Phase , Association International Conference , Mini Mental State Exam , Clinical Dementia Rating , Least Squared , Scientific Advisory Board , Data Safety Monitoring Board , Chief Executive Officer , Scientific Publications , National Institute , National Institutes , Global Statistical Test , Disease Assessment Scale Cognitive Subscale , Disease Cooperative Study Activities , Daily Living , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Media Contact , Nasdaq Atha , Nc , Biotechnology , Alzheimer 39 S ,